Zentalis Pharmaceuticals, Inc. (ZNTL)
Chart Events
Performance Outlook
| Previous Close | 21.23 |
| Open | 21.21 |
| Bid | 20.23 x 900 |
| Ask | 20.28 x 800 |
| Day's Range | 20.20 - 21.21 |
| 52 Week Range | 17.33 - 55.42 |
| Volume | |
| Avg. Volume | 573,773 |
| Market Cap | 1.165B |
| Beta (5Y Monthly) | 1.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.59 |
| Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 61.78 |
- GlobeNewswire
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that on February 1, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 12,500 shares of the Company’s common sto
- GlobeNewswire
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming investor conferences. Presentation Details: Event: Guggenheim Healthcare T
- Simply Wall St.
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
